
Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...


mRNA for Africa
The plant is expected to have the capacity to fill and package 500 million doses annually. German competitor BioNTech SE has also announced plans to...

Bavarian Nordic bags $225m for licence to RSV vaccine
Under the terms of the agreement, Bavarian Nordic A/S (Copenhagen) will receive an upfront payment of US$12.5m and potential milestone payments of up...

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....